Synopsis:- India’s largest pharmaceutical company closed FY26 with consolidated revenue near Rs. 58,200 crore, but the more consequential story sits inside a single business line: Innovative Medicines, which has compounded at 24 percent annually since FY21 and now accounts for 22 percent of sales, up from just 7.3 percent in FY18, raising the question of whether this segment can carry growth even as the core generics business matures.
A leading Indian pharmaceutical major has laid out its FY26 performance through a detailed investor presentation, and the headline revenue figure, while respectable, is not where the more interesting analysis lies. The company’s push into branded innovative medicines, a higher-margin, patent-protected category distinct from its traditional generics base, has quietly become a meaningfully larger share of the business than most casual observers may appreciate.
Sun Pharmaceutical Industries closed on Tuesday at Rs. 1,961.90, up 0.28 percent from its previous close of Rs.1,956.40 with a market capitalization of Rs.4,70,269.65 crore, and a P/E ratio near 40.59 times on trailing earnings.
The FY26 Numbers in Context
Consolidated sales increased by 12 percent from Rs. 52,041.2 crore in FY25 to Rs. 58,220.1 crore in FY26, while EBITDA grew 16 percent from Rs. 15,271.7 crore to Rs. 17,731.4 crore, with EBITDA margin expanding to 30.46 percent, the highest in the company’s five-year disclosures. Reported net profit rose 5 percent from Rs. 10,949.3 crore to Rs. 11,479.4 crore, while adjusted net profit increased 3.5 percent, reflecting a slower pace than revenue and EBITDA growth.
That gap between EBITDA growth and adjusted profit growth is worth sitting with. FY26 carried Rs. 920 crore in adjusted provisions related to litigation, wage code changes, and an asset impairment, a pattern that has repeated with some regularity across the past several years in this company’s results, and one investors should factor into how much weight they place on any single year’s reported profit figure.
Why Innovative Medicines Deserves Closer Attention
The segment has grown from $674 million (approximately Rs. 6,423.9 crore) in FY22 to $1,420 million (approximately Rs. 13,534.0 crore) in FY26, a compound annual growth rate of roughly 24 percent, comfortably outpacing the company’s overall consolidated growth rate over the same period. Its share of total sales has climbed from 7.3 percent in FY18 to 22 percent currently, a structural shift rather than a one-off spike.
The flagship product in this portfolio, Ilumya, generated $796 million (approximately Rs. 7,586.7 crore) in FY26 sales on its own, meaning a single branded drug now accounts for more than half of the entire Innovative Medicines revenue base. That concentration cuts both ways.
It demonstrates the segment can produce genuine blockbuster-scale products, but it also means the near-term trajectory of this growth engine is unusually dependent on one drug’s continued performance and patent runway, alongside a pipeline of five New Active Substances still working through preclinical to Phase 3 stages that have yet to generate meaningful revenue.
The US Business Tells a More Mixed Story
US formulations, the company’s single largest reporting segment at 29 percent of FY26 sales, grew just 3.6 percent for the full year and 4.5 percent in the fourth quarter specifically, a considerably slower pace than India formulations at 14 percent or Emerging Markets at close to 19 percent for the year.
Innovative Medicines revenue is embedded within the US and other segment totals rather than broken out as a standalone reporting line, which makes it difficult for outside investors to isolate exactly how much of the US segment’s modest growth is being propped up by Ilumya and other branded products against a softer core generics base.
This is a genuine analytical limitation in the disclosure, and retail investors should treat the 22 percent Innovative Medicines revenue share as a company-wide figure rather than assume it applies uniformly across every geography.
The Organon Acquisition
Separately, and arguably more consequential for the next few years than any single quarter’s numbers, the company has announced an acquisition of Organon & Co., a global women’s health and biosimilars business, in a deal management has described as EPS-accretive from the outset.
The transaction is priced at $14 per share, valuing the equity at close to $3.99 billion (approximately Rs. 38,028.7 crore), with pro-forma leverage around 2.3 times EBITDA and targeted cost synergies of roughly $350 million (approximately Rs. 3,335.9 crore) over two to four years.
Gross debt on the balance sheet already rose 118 percent year-on-year in FY26 to Rs. 4,080 crore, likely reflecting early financing steps tied to this transaction, even as the company maintains a substantial net cash position excluding debt of Rs. 30,140.Crores.
The Organon deal is a different kind of growth lever than Innovative Medicines, an acquired, diversified franchise rather than an organically built pipeline, and its integration execution over the coming quarters will matter as much to the investment case as anything happening within the existing Innovative Medicines segment.
What Retail Investors Should Weigh
The Innovative Medicines growth story is real and has genuinely re-shaped the revenue mix over eight years, but it currently rests heavily on one product’s continued strength, with the next wave of pipeline candidates still years from meaningful commercial contribution.
At a P/E near 40 times, the market is already pricing in continued execution on this front, alongside successful integration of a multi-billion-dollar acquisition still working through completion.
Investors should watch whether Innovative Medicines revenue disclosure becomes more granular by geography in coming quarters, since that would offer a clearer read on how dependent the US business specifically has become on this single growth engine.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
